NASDAQ · Biotechnology

Tevogen Bio Holdings Inc. (TVGN) Stock

$4.79 +6.68% NASDAQ: TVGN Healthcare

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology.

Valuation

MetricValue
Price$4.79
Market Cap$20.21M
P/E Ratio-0.77
P/B Ratio-1.59
P/S Ratio0.00
EPS (TTM)$-8.08
52-Week High$70.00
52-Week Low$3.64
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE241.39%
ROA-433.95%
ROCE902.44%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.31
Current Ratio0.29

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-5.0M$-1.0M$-9.0M$-54.0M$-26.0M
Net Profit$-16.0M$4.0M$-60.0M$-10.0M$-26.0M
EPS$-16.50$1.84$-0.02$-4.68$-8.08
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$8.0M$8.0M$6.0M$3.0M$4.0M
Total Liabilities$24.0M$42.0M$100.0M$10.0M$13.0M
Cash$7.0M$5.0M$1.0M$1.0M$1.0M
Borrowings$23.0M$40.0M$95.0M$3.0M$3.0M

Latest News

Tevogen Bio Holdings Inc. Becomes Tevogen Inc. GlobeNewswire · Jul 29, 2026 Tevogen Bio Announces 2026 Annual Meeting of Stockholders GlobeNewswire · Jul 14, 2026 Tevogen Announces Formation of a Healthcare Services Initiative GlobeNewswire · Jun 9, 2026 Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue GlobeNewswire · May 28, 2026 Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization GlobeNewswire · May 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-5.0M$-9.0M$-8.0M$-12.0M$-12.0M
Investing Cash Flow$0$-1.0M$0$0$0
Financing Cash Flow$0$0$0$0$3.0M
Net Cash Flow$7.0M$-2.0M$-4.0M$0$-1.0M
Free Cash Flow$-5.0M$-9.0M$-8.0M$-12.0M$-12.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-1.24
FCF Yield-59.37%
Quick Ratio0.29
Interest Coverage-212.10
Return 1Y-92.03%
Return 3Y-99.13%
Return 5Y—

Ownership

Insiders Held79.54%
Institutions Held3.24%
Institutions Float Held15.83%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC33,2482026-03-31
Blackrock Inc.24,3952026-03-31
Morgan Stanley17,3342026-03-31
Geode Capital Management, LLC15,7342026-03-31
Deutsche Bank AG15,3242026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATOS $2.36 -2.48% -1.23 $23.54M 0.00%
CGTX $0.89 +0.21% -3.94 $79.79M 0.00%
CLNNClene Inc. $5.29 -1.86% -1.66 $54.53M 0.00%
GLSI $14.36 +0.84% -21.98 $210.78M 0.00%
HURA $2.09 -2.34% -3.75 $133.10M 0.00%

About Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.

Tevogen Bio Holdings Inc. is led by CEO Ryan H. Saadi, employs 18 people, headquartered in US, publicly traded since 2022.

Tevogen Bio Holdings Inc. (TVGN) stock trades at $4.79 with a market capitalization of $20.21M. The stock is valued at a price-to-earnings (P/E) ratio of -0.77, price-to-book of -1.59, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.64 and $70.00, and currently trades 93.2% below its 52-week high.

On profitability, Tevogen Bio Holdings Inc. generates a return on equity (ROE) of 241.39% — well above the market average, a sign of a high-quality business, return on capital employed of 902.44%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: tevogen.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides